7TD1 image
Entry Detail
PDB ID:
7TD1
EMDB ID:
Title:
Lysophosphatidic acid receptor 1-Gi complex bound to LPA, state a
Biological Source:
PDB Version:
Deposition Date:
2021-12-30
Release Date:
2022-02-09
Method Details:
Experimental Method:
Resolution:
3.08 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Guanine nucleotide-binding protein G(i) subunit alpha-1
Mutations:G203A
Chain IDs:C (auth: A)
Chain Length:379
Number of Molecules:1
Biological Source:Rattus norvegicus
Polymer Type:polypeptide(L)
Description:Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
Chain IDs:B
Chain Length:340
Number of Molecules:1
Biological Source:Bos taurus
Polymer Type:polypeptide(L)
Description:Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2
Mutations:C68S
Chain IDs:D (auth: G)
Chain Length:71
Number of Molecules:1
Biological Source:Bos taurus
Polymer Type:polypeptide(L)
Description:Lysophosphatidic acid receptor 1
Chain IDs:A (auth: R)
Chain Length:350
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Differential activation mechanisms of lipid GPCRs by lysophosphatidic acid and sphingosine 1-phosphate.
Nat Commun 13 731 731 (2022)
PMID: 35136060 DOI: 10.1038/s41467-022-28417-2

Abstact

Lysophospholipids are bioactive lipids and can signal through G-protein-coupled receptors (GPCRs). The best studied lysophospholipids are lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P). The mechanisms of lysophospholipid recognition by an active GPCR, and the activations of lysophospholipid GPCR-G-protein complexes remain unclear. Here we report single-particle cryo-EM structures of human S1P receptor 1 (S1P1) and heterotrimeric Gi complexes formed with bound S1P or the multiple sclerosis (MS) treatment drug Siponimod, as well as human LPA receptor 1 (LPA1) and Gi complexes in the presence of LPA. Our structural and functional data provide insights into how LPA and S1P adopt different conformations to interact with their cognate GPCRs, the selectivity of the homologous lipid GPCRs for S1P versus LPA, and the different activation mechanisms of these GPCRs by LPA and S1P. Our studies also reveal specific optimization strategies to improve the MS-treating S1P1-targeting drugs.

Legend

Protein

Chemical

Disease

Primary Citation of related structures